MANNKIND CORP
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions focused on cardiometabolic and orphan lung diseases. The company develops and commercializes treatments addressing serious unmet medical needs including… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MANNKIND CORP does
In the company’s own words
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions focused on cardiometabolic and orphan lung diseases. The company develops and commercializes treatments addressing serious unmet medical needs including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
The company's cardiometabolic business comprises three commercial products. Afrezza is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, consisting of a dry powder formulation of human insulin delivered from a small portable inhaler. Furoscix is a novel subcutaneous formulation of furosemide delivering an 80 mg dose via an on-body infusor over five hours, indicated for edema treatment in pediatric and adult patients with chronic heart failure or chronic kidney disease. V-Go is a mechanical basal-bolus insulin delivery system worn like a patch that eliminates the need for multiple daily injections, acquired from Zealand Pharma in May 2022. The company acquired scPharmaceuticals Inc. in October 2025, which developed Furoscix and the ReadyFlow Autoinjector formulation.
MannKind's proprietary Technosphere drug delivery platform, based on the excipient fumaryl diketopiperazine, enables efficient pulmonary delivery of therapeutic agents. The company manufactures commercial-scale quantities of Afrezza and Tyvaso DPI inhalation powders at its Danbury, Connecticut facility, which has been certified to ISO 13485:2016 standards. Tyvaso DPI, developed using the Technosphere platform for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, is commercialized through a collaboration with United Therapeutics Corporation, which began marketing the product in June 2022.
The company's pipeline includes MNKD-201, a dry-powder formulation of nintedanib for idiopathic pulmonary fibrosis treatment, currently in Phase 1b and Phase 2 clinical studies. MNKD-701 represents another pipeline opportunity focused on formulating bumetanide as an inhalable dry powder. The company holds an extensive intellectual property portfolio comprising approximately 1,100 issued patents and 310 pending patent applications worldwide, with Afrezza protected by approximately 580 issued patents and Tyvaso DPI by approximately 600 issued patents. More information is available at www.mannkindcorp.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- DANBURY, CT
- Fiscal year end
- December
- CIK
- 899460
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MANNKIND CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MANNKIND CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MANNKIND CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MANNKIND CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MANNKIND CORP's last four quarterly filings that the numbers alone won't show?”